132 studies (12 from unattributed sources) on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Hk Peptides | 135 | 99.77% | View COA → |
| Lilipeptide | 126 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 125 | 99.45% | View COA → |
| Qing Li Peptide | 116 | 99.62% | View COA → |
| Nexaph | 114 | 99.41% | View COA → |
| Bfflist Amo | 105 | 99.71% | View COA → |
| Zlz Peptide | 95 | 99.78% | View COA → |
| Reta Peptide | 79 | 99.7% | View COA → |
Recent certificates: #16690 (99.524%) · #23591 (99.862%) · #16764 (99.522%) · #16766 (99.876%) · #21928 (99.9%) · #21929 (99.9%)
Manufacturers with published third-party certificates of analysis for Retatrutide. Open a vendor to see every batch we've verified.
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of…
Understanding the detailed metabolome and lipidome shifts induced by retatrutide could provide critical insights into its multi-faceted benefits beyond simple weight loss and glycemic control. For peptide users and cl…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
This review underscores the transformative potential of novel antiobesity medications in improving cardiovascular health outcomes for obese patients. The demonstrated 20% reduction in MACE by semaglutide sets a new be…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer …
The meta-analysis revealed significant improvements in metabolic parameters among kidney transplant recipients treated with GLP-1 RAs. Patients experienced a mean weight loss of 4.5 kg (p<0.001) and a reduction in HbA…
This review significantly advances our understanding of GLP-1's extensive therapeutic potential, moving beyond its established role in metabolic health. The detailed exploration of its neuroprotective mechanisms sugge…
This research provides critical reassurance regarding the safety and efficacy of GLP-1 receptor agonists for obesity management. The preservation of muscle mass and function during weight loss is a significant clinica…
This research provides crucial insights into the pleiotropic effects of Retatrutide, extending its known benefits beyond weight loss and glycemic control to direct adipose tissue repair. The ability of Retatrutide to …
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
This trial is crucial because retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, holds significant promise for treating obesity and its complex comorbidities. If successful, it could off…
Ensuring bioequivalence and safety across different drug delivery devices is a critical step in pharmaceutical development and patient access. If the Test Device proves to be bioequivalent and equally safe, it could f…
The initiation of this large-scale clinical trial for Retatrutide is a pivotal step towards addressing the interconnected epidemics of Type 2 Diabetes and obesity with a single, highly potent therapeutic agent. If suc…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The findings from this trial are highly anticipated, as obesity is a major driver of osteoarthritis progression and a significant barrier to effective management. Retatrutide's ability to induce substantial weight los…
The successful modulation of calorie intake and energy expenditure by LY3437943 could represent a significant advancement in obesity treatment. If LY3437943 demonstrates a favorable impact on these parameters, it coul…
If successful, this study could demonstrate a significant cardio-renal protective effect of Retatrutide beyond its known weight-loss benefits. This would be a crucial advancement, as current treatments for obesity oft…
The SYNERGY-OUTCOMES study holds immense significance as it addresses a critical unmet medical need for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition without approved pharmacologic trea…
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The e…
A favorable drug-drug interaction profile is a critical factor for the successful development of any new medication, particularly for chronic conditions like obesity where patients often take multiple concomitant drug…
This Phase 3b trial is pivotal for optimizing Retatrutide's clinical utility by identifying the most effective and well-tolerated dosing strategies for long-term use. Understanding the nuances of dose escalation can s…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
Understanding how kidney function affects LY3437943's pharmacokinetics is crucial for ensuring patient safety and guiding appropriate dosing strategies across diverse populations. This data is essential for developing…
This head-to-head Phase 3 trial is critically important because it directly compares retatrutide, a potential best-in-class GLP-1/GIP/Glucagon receptor triple-agonist, against semaglutide, a leading GLP-1 receptor ago…
If successful, this Phase 3b trial could establish Retatrutide as a highly effective and safe treatment option for obesity and overweight, potentially offering superior weight loss outcomes compared to existing therap…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This comprehensive review underscores the transformative potential of incretin polyagonists to redefine obesity treatment paradigms. By offering a non-surgical option with efficacy approaching that of bariatric surger…
This comprehensive review is critical for guiding clinicians and policymakers in India to implement evidence-based and effective obesity management strategies. By synthesizing the latest data and expert consensus from…
The findings underscore the critical role of multi-targeted approaches in effectively treating the complex pathology of MASLD. This comprehensive overview provides a roadmap for future drug development, emphasizing th…
This review underscores the rapid and profound evolution of obesity pharmacotherapy, offering unprecedented hope for patients struggling with chronic weight management. The development of highly effective drugs like G…
This hypothetical study strongly suggests that integrating resistance exercise with incretin-based weight loss pharmacotherapy is critical for optimizing body composition, mitigating sarcopenia (age-related muscle los…
This study highlights a critical issue: the lack of diverse representation and transparent reporting in obesity clinical trials significantly limits the generalizability and safety assessment of new medications. If tr…
The development of oral GLP-1 RAs represents a significant leap forward, offering a more convenient and patient-friendly option that can greatly improve adherence to treatment for Type 2 Diabetes. Furthermore, the adv…
Free, no account — handy when you're working with Retatrutide.